

**Eisai Co., Ltd.** 4-6-10 Koike Bldg. 12F, 1-1-1, Higashi-Shinjyuku, Shinjyuku-ku, Tokyo 162-8502, Japan  
also significantly impacts the lives of their families and caregivers as well as society as a whole.  
Phone: 03-3817-5120 Fax: 03-3811-3077

Eisai hopes that the 23 mg Aricept extended release tablet will provide a valuable new treatment option for patients with moderate to severe AD and healthcare professionals. In addition to developing new formulations of Aricept, Eisai is committed to working on new AD treatments, actively conducting disease awareness activities and providing support to patients